PYRROLOPYRIMIDINE COMPOUNDS AND APPLICATION THEREOF Russian patent published in 2015 - IPC C07D487/04 A61K31/519 A61P35/00 A61P29/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pyrrolopyrimidine compounds of formula (I), which possess properties of an inhibitor of at least one kinase, selected from JAK1, JAK2, JAK3 and TYK2, or their pharmaceutically acceptable salt. In formula (I) compound:

,

R¹ is selected from hydrogen, C₁-C₄alkyl, C₃-C₆cycloalkyl; R² is selected from aryl, heterocycle, heteroaryl, -C(O)NR^cR^d, -S(O)_nR^f and -S(O)_nNR^cR^d, and each of the said alkyl, aryl, cycloalkyl, heterocycle, heteroaryl in R¹ and R² is possibly substituted with one or more groups, selected from a possibly substituted C₁-C₄alkyl, possibly substituted aryl, possibly substituted C₂-C₆alkinyl, C₃-C₆cycloalkyl, -C(O)OR^b, -CN, -C(O)NR^cR^d, halogen, possibly substituted heterocycle, possibly substituted heteroaryl, NR^cR^d, -NR^eC(O)R^a, -NR^eS(O)_nR^f, -NO₂, -OR^b, -S(O)_nR^f and -S(O)_nNR^cR^d; m equals 1 and n equals 2; in each case R^a, R^b, R^c, R^d, R^e and R^f each is independently selected from hydrogen, possibly substituted C₁-C₄alkyl, possibly substituted C₂-C₆alkinyl, possibly substituted C₃-C₆cycloalkyl, possibly substituted aryl, possibly substituted heteroaryl and possibly substituted heterocycle; or R^c and R^d with a nitrogen atom, which they are bound to, form a heterocyclic ring, which is possibly substituted with one or more groups, selected from halogen, C₁-C₄alkyl, hydroxyl and C₁-C₄alkoxy, where the heterocyclic ring also possibly contains one or two additional heteroatoms, selected from N, O and S; where each possibly substituted the said group can be non-substituted or independently substituted with one or more substituents, independently selected from C₁-C₄alkyl, C₃-C₆cycloalkyl, aryl, heterocycle, C₁-C₄haloalkyl, -OC₁-C₄alkyl, -C₁-C₄alkyl-O-C₁-C₄alkyl, halogen, -OH, -NH₂, -N(C₁-C₄alkyl)(C₁-C₄alkyl), -CN, and -NO₂, in which each aryl, heterocycle are possibly substituted with one or more groups, selected from halogen and C₁-C₄alkyl.

EFFECT: obtaining a medication for the treatment of an inflammatory disease or cancer, sensitive to the inhibition of at least one kinase of the said kinases, is achieved.

24 cl, 1 tbl, 3 ex